Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
March 29, 2023 08:00 ET
|
Axial Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 – – IND-enabling studies ongoing for Parkinson’s Disease development...
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
December 15, 2022 08:42 ET
|
Clinical Ink
Horsham, PA, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease...
H2o Therapeutics Gets FDA Clearance for Its Apple Watch-Based App for Parkinson's Disease
November 20, 2022 09:01 ET
|
h2o therapeutics
ANKARA, Turkey, Nov. 20, 2022 (GLOBE NEWSWIRE) -- Digital health start-up H2o therapeutics received 510(k) marketing clearance from the U.S. Food and Drug Administration for its prescription mobile...
Worldwide Neurorehabilitation Industry to 2030 - Rising Demand of Telerehabilitation Presents Opportunities
February 17, 2022 05:43 ET
|
Research and Markets
Dublin, Feb. 17, 2022 (GLOBE NEWSWIRE) -- The "Neurorehabilitation Market by Type, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to...
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned
December 02, 2019 13:00 ET
|
Herantis Pharma Oyj
Herantis Pharma Plc's directed share issue is oversubscribed multiple times and completed as planned Herantis Pharma Plc Company release 2 December 2019 at 8:00 pm THE INFORMATION CONTAINED IN...
Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellusti
December 02, 2019 13:00 ET
|
Herantis Pharma Oyj
Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellusti Herantis Pharma Oyj Yhtiötiedote 2.12.2019 kello 20:00 TÄMÄN TIEDOTTEEN SISÄLTÄMÄ TIETO EI...
Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial
September 26, 2019 02:00 ET
|
Herantis Pharma Oyj
Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial Herantis Pharma Plc Company release 26 September 2019 at 9:00 AM Herantis Pharma Plc (“Herantis” or “Company”)...
Herantis Pharma Oyj päivittää käynnissä olevan Vaiheen 1-2 CDNF-tutkimuksen aikataulua
September 26, 2019 02:00 ET
|
Herantis Pharma Oyj
Herantis Pharma Oyj päivittää käynnissä olevan Vaiheen 1-2 CDNF-tutkimuksen aikataulua Herantis Pharma Oyj Yhtiötiedote 26.9.2019 kello 9:00 Herantis Pharma Oyj (“Herantis” tai “Yhtiö”) tiedotti...
Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million
March 12, 2019 11:00 ET
|
Herantis Pharma Oyj
Herantis Pharma Plc Announces Positive Outcome of Directed Share Issue Raising EUR 5.8 Million Herantis Pharma Plc Company release 12 March 2019, 5:00 pm Not for publication or distribution,...
Herantis Pharma Oyj tiedottaa onnistuneesta noin 5,8 miljoonan euron suunnatusta osakeannista
March 12, 2019 11:00 ET
|
Herantis Pharma Oyj
Herantis Pharma Oyj tiedottaa onnistuneesta noin 5,8 miljoonan euron suunnatusta osakeannista Herantis Pharma Oyj Yhtiötiedote 12.3.2019 kello 17:00 Ei julkistettavaksi tai levitettäväksi, suoraan...